mannanbind
lectin
mbl
plasma
protein
innat
immun
system
abil
initi
antimicrobi
inflammatori
action
mbl
defici
common
gener
popul
may
depend
definit
classifi
mbl
defici
underlin
redund
immun
system
ongo
research
attempt
illumin
condit
mbl
defici
may
lead
diseas
exampl
review
illustr
divers
result
obtain
far
innat
immun
system
attract
interest
action
immedi
defenc
infect
also
import
activ
adequ
specif
immun
respons
number
differ
molecul
involv
recogn
foreign
agent
structur
display
surfac
socal
pathogen
associ
molecular
pattern
pamp
recognit
molecul
may
cellassoci
receptor
pathogen
recogn
receptor
prp
solubl
pathogen
recogn
molecul
prm
latter
group
includ
collectin
among
mannanbind
lectin
mbl
attract
especi
interest
due
abil
bind
microorgan
jack
turner
lead
activ
complement
system
blood
mbl
associ
mblassoci
serin
proteas
masp
function
masp
known
although
clear
enzym
mblmasp
complex
need
activ
complement
factor
thiel
et
al
late
found
anoth
group
prm
ficolin
may
activ
enzymat
cascad
complement
use
masp
mbl
involv
mbl
defenc
system
studi
extens
littl
present
known
function
ficolin
detail
present
protein
see
holmskov
et
al
mbl
discov
rabbit
protein
bind
mannan
term
mannanbind
protein
mbp
kawasaki
et
al
later
term
mannosebind
protein
introduc
unfortun
impli
select
reactiv
characterist
protein
burst
investig
mbl
defici
suscept
infecti
diseas
rous
semin
demonstr
low
mbl
level
children
defici
opson
activ
suffer
unexplain
sensit
infect
super
et
al
initi
investig
causal
relationship
mbl
diseas
suscept
reli
quantif
mbl
serum
plasma
case
opson
activ
howev
find
genet
influenc
mbl
level
review
nuytinck
shapiro
open
determin
mbl
statu
genotyp
due
simplic
allotyp
mani
paper
publish
base
sole
genotyp
use
conclus
may
drawn
studi
ought
realiz
individu
ident
genotyp
known
mbl
variant
may
differ
mbl
level
steffensen
et
al
interindividu
level
mbl
vari
approxim
ng
individu
complet
defici
mbl
yet
report
gml
level
mbl
individu
quit
stabl
throughout
life
birth
level
adult
level
reach
month
minor
declin
old
age
small
increas
connect
acut
phase
respons
thiel
et
al
increas
slow
week
induc
event
modest
threefold
increas
compar
genet
base
increas
unfortun
led
promot
mbl
acut
phase
protein
inde
formal
right
howev
would
rather
focu
mbl
protein
present
need
capabl
immedi
action
gene
encod
mbl
pseudogen
locat
chromosom
contain
four
exon
number
snp
character
gene
exon
harbour
three
missens
snp
give
rise
amino
acid
exchang
first
part
collagen
region
two
name
b
c
exchang
glycin
acet
amino
acid
third
introduc
cystein
collagen
region
residu
number
includ
leader
sequenc
residu
wild
type
denot
three
variant
structur
allel
associ
decreas
mbl
level
promot
region
show
number
snp
well
influenc
express
mbl
address
polymorph
term
hl
term
yx
term
pq
due
linkag
disequilibrium
seven
haplotyp
found
hypa
lypa
lyqa
lxpa
hypd
lypb
lyqc
give
total
possibl
genotyp
eg
mbl
defici
genotyp
lxpalypb
individu
homozyg
show
mbl
level
gml
except
homozyg
lxpa
heterozyg
peopl
one
gene
b
c
mostli
mbl
level
gml
variant
structur
allotyp
gene
genotyp
often
denot
show
mbl
level
ngml
low
level
also
found
individu
lxpa
one
gene
b
c
frequenc
haplotyp
differ
ethnic
group
eg
lypb
common
variant
haplotyp
caucasian
asian
rare
african
contrast
lyqc
common
variant
haplotyp
african
rare
found
caucasian
asian
peopl
alway
realiz
lxpa
haplotyp
gene
frequenc
common
caus
mbl
defici
caucasian
either
present
homozyg
lxpa
individu
concentr
somewhat
unpredict
concert
variant
haplotyp
alway
result
low
level
mbl
genotyp
method
evolv
along
invent
molecular
biolog
today
fairli
labour
intens
cheap
addit
high
throughput
robot
method
use
method
mention
skalnikova
et
al
simpl
membran
strip
genotyp
kit
recent
made
avail
innogenet
nv
gent
belgium
nuytinck
shapiro
problem
genotyp
archiv
patient
sampl
often
compris
plasma
serum
devoid
cell
possibl
retriev
dna
serum
larg
volum
need
usual
l
success
dna
also
amplifi
paraffin
embed
tissu
section
despit
socal
acutephaselik
charact
discuss
one
may
argu
whatev
may
caus
low
mbl
actual
concentr
mbl
level
function
activ
interest
measur
mbl
easi
today
sever
commerci
supplier
elisa
kit
sanquin
reagent
amsterdam
netherland
hycult
biotechnolog
leiden
netherland
antibodyshop
copenhagen
denmark
dobeel
corp
south
korea
experi
unpublish
work
satisfactorili
measur
level
compar
determin
inhous
assay
base
catch
mbl
onto
mannan
surfac
follow
detect
bound
mbl
mab
antimbl
antibodi
thiel
et
al
function
assay
mbl
estim
lectin
activ
somewhat
surprisingli
give
exactli
result
sandwich
assay
employ
coat
mab
develop
biotinyl
mab
thiel
et
al
presenc
small
amount
nonmannanbind
lower
molecular
size
mbl
variant
structur
allotyp
individu
note
lipscomb
et
al
gar
et
al
one
wish
aberr
mbl
may
measur
sandwich
assay
suitabl
antibodi
note
assay
use
mannan
coat
develop
antimbl
antibodi
estim
mbl
lectin
thu
repres
function
assay
initi
step
activ
mbl
pathway
one
wish
estim
activ
mblmasp
complex
thu
measur
mbl
pathway
activ
one
may
simpli
carri
incub
dilut
serum
sampl
c
develop
antibodi
determin
amount
bound
surfac
surprisingli
appear
high
serum
dilut
littl
activ
via
classic
pathway
bound
antimannan
antibodi
super
et
al
nevertheless
safe
side
chosen
take
advantag
observ
complex
unstabl
high
ionic
strength
mblmasp
complex
stay
intact
thu
sampl
serum
plasma
high
salt
also
abolish
coagul
dilut
buffer
contain
nacl
calcium
follow
incub
mannanco
well
wash
ad
deposit
estim
incub
c
result
assay
correl
r
assay
mbl
lectin
antigen
thiel
et
al
except
case
defici
stengaardpedersen
et
al
recent
kit
estim
function
activ
entir
mbl
pathway
made
commerci
avail
wieslab
lund
sweden
assay
measur
amount
solubl
membran
attack
complex
deposit
mannan
surfac
follow
incub
serum
c
thu
sensit
defect
compon
mbl
may
note
prefer
term
lectin
pathway
sinc
land
hficolin
appear
function
like
mbl
howev
lficolin
lectin
molecul
indiscrimin
activ
toward
acetyl
group
krarup
et
al
numer
studi
examin
relationship
infecti
diseas
mbl
level
andor
mbl
genotyp
limit
space
allow
mention
instead
focu
illustr
differ
aspect
associ
studi
comprehens
discuss
mbl
infecti
diseas
refer
recent
review
eg
nuytinck
shapiro
eisen
minchinton
kilpatrick
stress
major
individu
gener
popul
low
mbl
level
suffer
condit
high
level
mbl
seem
problem
thu
epidemiolog
studi
encompass
almost
adult
fail
observ
consequ
variant
allotyp
dahl
et
al
studi
focuss
patient
tertiari
referr
hospit
eg
gar
et
al
summerfield
et
al
cover
much
larger
background
popul
find
convinc
associ
infect
variant
allotyp
address
possibl
correl
mbl
level
clinic
condit
issu
defin
mbl
defici
physiolog
relev
mbl
level
lead
clinic
manifest
like
differ
differ
diseas
exampl
given
number
differ
level
use
cutoff
valu
defin
mbl
defienc
judg
clinic
trial
appear
least
ng
mblml
plasma
need
reconstitut
vitro
function
activ
deposit
mbl
infus
mbl
defici
individu
valdimarsson
et
al
hand
investig
leukaemia
patient
suggest
cutoff
level
ngml
peterslund
et
al
even
gml
neth
et
al
case
obstetr
problem
even
lower
level
ngml
use
chemotherapi
induc
neutropenia
increas
risk
infect
chemotherapi
period
may
thu
uniqu
situat
studi
role
mbl
context
iatrogen
immunodefici
sever
studi
thu
attempt
analyz
correl
mbl
defici
infect
patient
turn
fairli
difficult
compar
studi
due
number
aspect
studi
includ
patient
varieti
underli
malign
thu
differ
chemotherapi
regim
use
studi
examin
mbl
genotyp
may
case
disregard
strong
influenc
promot
allotyp
lxpa
other
use
mbl
level
outcom
measur
differ
studi
durat
fever
neutropeniaseri
infect
variat
definit
differ
combin
antimicrobi
agent
gcsf
use
differ
center
studi
period
differ
prospect
retrospect
may
present
difficulti
due
variabl
journal
keep
eg
registr
febril
episod
emerg
indic
increas
infect
patient
low
mbl
level
seen
studi
seem
absent
much
less
pronounc
patient
particular
strong
suppress
phagocyt
activ
due
intens
chemotherapi
prepar
patient
bone
marrow
transplant
caus
specif
leukemia
aml
shall
first
describ
report
find
clear
evid
import
mbl
protect
leukemia
patient
turn
report
correl
found
neth
et
al
examin
children
receiv
chemotherapi
mbl
genotyp
mbl
level
correl
caus
frequenc
durat
febril
neutropen
period
major
children
diagnos
acut
lymphoblast
leukemia
children
variant
mbl
allel
exhibit
twice
mani
day
febril
neutropenia
children
wild
type
genotyp
p
episod
febril
neutropenia
also
significantli
longer
group
children
variant
genotyp
analysi
mbl
quantif
support
children
less
g
mblml
higher
number
day
febril
neutropenia
p
signific
relationship
observ
frequenc
infect
measur
clinic
paramet
mbl
genotyp
peterslund
et
al
describ
adult
treat
chemotherapi
rang
hematolog
malign
within
day
start
chemotherapi
patient
develop
clinic
signific
infect
defin
bacteremia
pneumonia
mbl
level
measur
plasma
obtain
chemotherapi
lower
patient
one
without
infect
p
patient
infect
except
one
show
mbl
level
gml
spur
studi
vekeman
et
al
conduct
prospect
observ
studi
focus
assess
mbl
risk
factor
infect
chemotherapyinduc
neutropenia
adult
hematolog
cancer
patient
includ
patient
determin
mbl
level
well
mbl
genotyp
analysi
perform
per
patient
basi
higher
rate
sever
infect
seen
mbl
defici
patient
p
impact
increas
exclud
acut
leukaem
patient
focus
bacteremia
exclud
acut
leukemia
bone
marrow
transplant
patient
mbl
defici
associ
greater
rate
bacteremia
p
associ
low
mbl
infect
independ
whether
patient
receiv
prophylact
antibiot
gmcsf
focus
aml
patient
alon
correl
low
mbl
infect
author
see
differ
durat
febril
neutropenia
group
bergmann
et
al
studi
adult
patient
acut
myeloid
leukemia
aml
determin
mbl
level
observ
influenc
mbl
level
frequenc
sever
durat
fever
suggest
sever
immunosuppress
induc
combin
myeloid
cancer
chemotherapi
may
obscur
normal
effector
function
mbl
line
kilpatrick
et
al
fail
see
anyth
modest
effect
mbl
level
ngml
retrospect
studi
patient
prepar
bmt
half
present
aml
genotyp
determin
anoth
studi
rocha
et
al
see
relationship
exon
allotyp
promot
allotyp
determin
posttranspl
infect
followup
period
day
donorrecipi
pair
patient
acut
n
chronic
leukemia
n
hlaident
sibl
bone
marrow
transplant
convers
mullighan
et
al
studi
mbl
genotyp
allogen
stem
cell
transplant
recipi
n
donor
n
record
retrospect
infect
burden
rather
timetofirstinfect
use
rel
long
year
patient
followup
period
found
presenc
haplotyp
hya
ci
wild
type
gene
ie
genotyp
encod
higher
mbl
level
associ
reduc
risk
infect
especi
period
neutrophil
recoveri
surprisingli
associ
seen
donor
recipi
haplotyp
thu
significantli
frequent
infect
seen
donor
carri
mbl
mutat
use
theori
explain
influenc
donor
mbl
allotyp
although
suggest
mbl
may
synthes
donor
cell
retrospect
studi
horiuchi
et
al
examin
infect
patient
undergo
high
dose
therapi
hdt
follow
autolog
peripher
blood
stem
cell
transplant
autopbsct
patient
includ
nonhodgkin
lymphoma
n
acut
myeloid
leukemia
n
acut
lymphoid
leukemia
n
patient
found
carri
defici
genotyp
bb
blxa
associ
higher
risk
contract
major
bacteri
infect
microbiolog
confirm
system
dissemin
infect
day
follow
autopbsct
treatment
patient
receiv
prophylact
antibiot
author
suggest
varieti
factor
due
presenc
donor
cell
allogen
stem
cell
transplant
influenc
analys
thu
hdt
follow
autopbsct
may
prove
good
model
analyz
contribut
mbl
level
infect
myeloabl
treatment
studi
aittoniemi
et
al
patient
chronic
lymphocyt
leukemia
tacx
et
al
patient
new
onset
fever
admit
intern
medicin
depart
detail
observ
effect
mbl
infect
mention
begin
section
numer
differ
found
studi
conduct
critic
factor
may
differ
intens
condit
regim
use
lead
variou
level
durat
neutropenia
well
variat
followup
period
hope
studi
describ
patient
particularli
risk
mbl
defici
system
inflammatori
respons
syndrom
sir
develop
patient
major
oper
bone
case
sir
occur
respons
infect
sepsi
use
describ
symptom
sever
septic
shock
may
develop
multi
organ
dysfunct
mod
condit
present
major
challeng
inde
critic
ill
patient
may
classifi
sirssepsi
larg
number
studi
tri
identifi
risk
marker
hansen
et
al
studi
patient
randomli
assign
either
convent
treatment
intens
insulin
therapi
intens
care
unit
icu
patient
need
prolong
intens
care
day
includ
mbl
concentr
measur
admiss
day
last
day
icu
group
convent
treat
patient
die
predominantli
sepsi
mod
significantli
threefold
lower
mbl
level
upon
admiss
survivor
p
intens
insulin
therapi
significantli
reduc
mortal
sepsi
mod
lack
signific
associ
mbl
level
outcom
may
thu
due
small
number
case
anoth
care
conduct
studi
investig
mbl
level
genotyp
total
adult
sepsi
prospect
admit
icu
gar
et
al
differ
seen
genotyp
frequenc
patient
sir
compar
healthi
control
frequenc
mbl
variant
genotyp
significantli
higher
patient
sepsi
compar
patient
without
sepsi
p
risk
ratio
develop
sever
sepsi
septic
shock
rang
time
higher
patient
ao
oo
versu
aa
genotyp
mbl
level
invers
relat
sever
sepsi
p
increas
risk
fatal
outcom
patient
die
observ
patient
variant
mbl
allel
look
adult
patient
admit
mix
medicalsurg
icu
sutherland
et
al
character
mbl
genotyp
critic
ill
caucasian
sir
patient
divid
high
low
mbl
haplotyp
group
patient
low
mbl
haplotyp
group
significantli
increas
preval
posit
bacteri
cultur
admiss
icu
p
patient
low
mbl
haplotyp
group
significantli
increas
rate
sepsi
septic
shock
admiss
icu
surviv
day
differ
significantli
low
mbl
haplotyp
high
mbl
haplotyp
group
fidler
et
al
analyz
mbl
genotyp
level
total
critic
ill
children
infecti
noninfecti
insult
admit
pediatr
icu
sevenfold
confid
interv
p
greater
risk
develop
sir
within
h
admiss
patient
observ
carri
mbl
variant
allel
wild
type
allel
ao
oo
versu
aa
signific
associ
also
found
sever
system
respons
infect
presenc
mbl
mutat
p
sever
ill
among
patient
admit
infect
divid
local
infect
sepsi
septic
shock
median
mbl
level
invers
relat
sever
children
mbl
level
ngml
greater
chanc
develop
sir
versu
studi
frequenc
sepsi
low
birth
weight
infant
includ
patient
develop
cultur
proven
sepsi
reveal
statist
signific
clinic
data
infant
without
specif
mutat
number
gene
includ
mbl
genotyp
ahren
et
al
immun
defens
compromis
trauma
involv
major
oper
patient
thu
increas
risk
infect
follow
major
surgeri
particular
interest
cancer
sinc
recurr
rate
significantli
higher
surviv
period
shorter
patient
suffer
postoper
infect
report
patient
undergo
major
elect
gastrointestin
surgeri
malign
diseas
siassi
et
al
report
patient
develop
sepsi
sir
show
significantli
lower
mean
postop
mbl
level
p
addit
ytting
et
al
report
significantli
increas
frequenc
pneumonia
primari
oper
colorect
cancer
patient
low
mbl
level
p
mbl
defici
appear
play
import
role
suscept
critic
ill
patient
develop
progress
sepsi
septic
shock
confer
substanti
increas
risk
fatal
outcom
clearli
need
improv
defin
patient
group
clinic
data
relev
examin
etiolog
autoimmun
diseas
larg
unknown
initi
infect
presenc
inflammatori
process
involv
complement
compon
process
spur
number
studi
associ
mbl
studi
associ
mbl
defici
rheumatoid
arthriti
ra
discuss
detail
graudal
barton
et
al
shall
thu
go
detail
depend
ethnic
group
type
patient
symptom
studi
associ
seen
studi
balanc
indic
low
mbl
level
may
link
symptom
indic
poor
prognosi
well
earlier
debut
sever
investig
mbl
system
lupu
erythematosu
sle
consensu
emerg
low
level
mbl
predispos
develop
diseas
certainli
connect
like
sle
develop
almost
rare
case
defici
rather
may
mbl
defici
aggrav
diseas
develop
consequ
earlier
diagnosi
achiev
summari
studi
mbl
sle
may
found
paper
gar
et
al
perform
metaanalysi
eg
ohlenschlaeg
et
al
takahashi
et
al
sle
patient
mbl
defici
increas
risk
respiratori
tract
infect
gar
et
al
takahashi
et
al
well
risk
develop
arteri
thrombos
patient
includ
develop
arteri
thrombosi
hazard
ratio
correct
known
risk
factor
ohlenschlaeg
et
al
celiac
diseas
multi
factori
disord
strong
allerg
reaction
gluten
small
intestin
develop
link
hla
haplotyp
studi
boniotto
et
al
encompass
patient
control
indic
associ
celiac
diseas
presenc
variant
mbl
allel
later
group
boniotto
et
al
press
investig
patient
control
found
frequenc
homozygos
variant
mbl
allel
higher
patient
p
low
mbl
genotyp
strongli
associ
celiac
diseas
symptom
p
well
increas
frequenc
secondari
autoimmun
diseas
p
immunohistochemistri
mbl
found
present
togeth
apoptot
cell
basal
lamina
intestin
epithelium
previous
found
mrna
mbl
boniotto
et
al
find
itali
support
finnish
celiac
diseas
patient
iltanen
et
al
thu
found
associ
b
allotyp
mbl
studi
celiac
diseas
patient
control
p
boniotto
et
al
press
suggest
impair
remov
apoptot
cell
due
mbl
defici
might
predispos
develop
autoimmun
symptom
recent
paper
describ
mice
lack
mbl
exhibit
less
effici
remov
apoptot
cell
stuart
et
al
vitro
studi
previous
implic
mbl
remov
apoptot
cell
ogden
et
al
nauta
et
al
anoth
explan
could
increas
suscept
intestin
infect
diarrhea
associ
low
mbl
may
chang
intestin
epithelia
thu
allow
abnorm
stimul
antigliadin
immun
respons
trigger
cascad
lead
celiac
diseas
possibl
mbl
involv
also
consid
two
inflammatori
bowel
diseas
ibd
ulcer
coliti
uc
cohn
diseas
cd
pathogenesi
unknown
genet
well
environment
factor
eg
microorgan
implic
rector
et
al
examin
mbl
genotyp
ibd
patient
uc
cd
indetermin
coliti
compar
affect
nonaffect
firstdegre
rel
healthi
control
number
individu
low
mbl
variant
haplotyp
significantli
lower
uc
compar
cd
p
control
p
differ
found
cd
control
suggest
mbl
may
respons
extens
complementmedi
mucos
damag
uc
compar
cd
low
mbl
level
could
thu
protect
somewhat
develop
diseas
seibold
et
al
conduct
smaller
studi
measur
mbl
level
cd
uc
healthi
control
mbl
genotyp
cd
uc
control
exclud
patient
activ
diseas
studi
frequenc
homozyg
compound
heterozyg
variant
exon
allel
differ
significantli
patient
suffer
cd
uc
healthi
control
p
cd
patient
control
consid
signific
increas
p
antibodi
mannan
saccharomyc
cerevisia
present
mani
patient
cd
routin
clinic
paramet
studi
patient
cd
control
found
cd
patient
antimannan
antibodi
low
mbl
level
p
also
true
look
tcell
prolifer
respons
mannan
p
would
appear
immun
reactiv
mannan
cd
regul
mbl
concentr
studi
mbl
ibd
seem
like
profound
potenti
use
inform
may
gain
extend
studi
seem
delic
balanc
mbl
level
may
involv
harm
benefici
inflamm
cardiovascular
system
exampl
given
kawasaki
diseas
system
vascul
childhood
possibl
caus
infect
vascul
predilect
coronari
arteri
develop
world
kawasaki
diseas
common
caus
acquir
heart
diseas
children
royl
et
al
base
idea
mbl
initi
inflamm
biezeveld
et
al
studi
frequenc
mbl
genotyp
dutch
patient
kawasaki
diseas
found
higher
frequenc
mbl
mutat
compar
genotyp
control
p
children
younger
year
mutat
higher
risk
develop
coronari
arteri
lesion
p
kawasaki
diseas
occur
frequent
orient
children
roughli
time
frequent
caucasian
royl
et
al
studi
kawasaki
diseas
among
hong
kong
chines
patient
cheung
et
al
includ
patient
match
control
determin
mbl
genotyp
mbl
level
see
differ
mbl
genotyp
patient
control
analyz
brachioradi
arteri
stiff
import
cardiovascular
risk
factor
children
found
associ
low
mbl
genotyp
multipl
linear
regress
analysi
p
conclud
mbl
genotyp
may
modul
diseas
recent
find
associ
novel
human
coronaviru
kawasaki
diseas
esper
et
al
may
fit
mani
indic
mbl
antivir
activ
plaqu
materi
may
remov
insid
carotid
arteri
eg
endarterectomi
avoid
cerebr
attack
restenosi
often
occur
procedur
typic
patient
first
year
prospect
studi
patient
rugonfalvikiss
et
al
indic
femal
patient
genotyp
associ
lower
mbl
level
slower
rate
earli
restenosi
suggest
high
level
mbl
may
part
pathophysiolog
condit
studi
heart
transplant
recipi
fian
et
al
record
transplantassoci
coronari
arteri
diseas
observ
associ
mbl
defici
p
also
record
acut
reject
transplant
seen
mbl
defici
compar
higher
mbl
level
p
assum
mbl
may
interact
transplant
tissu
initi
complement
activ
studi
thu
add
list
studi
suggest
complement
activ
harm
endothelium
gener
possibl
allograft
endothelium
particular
atherosclerosi
main
caus
morbid
western
world
sinc
inflammatori
reaction
involv
damag
endothelium
studi
also
aim
examin
possibl
correl
mbl
studi
patient
sever
atherosclerosi
madsen
et
al
found
patient
myocardi
infarct
among
norwegian
low
mbl
allotyp
control
rel
risk
p
saevarsdottir
et
al
found
cohort
studi
iceland
includ
crosssect
group
nest
control
sampl
individu
risk
develop
myocardi
infarct
higher
mbl
defici
individu
known
type
diabet
patient
high
risk
microand
macrovascular
complic
possibl
due
inflammatori
reaction
propos
mbl
may
bind
alter
self
compon
may
possibl
found
diabet
patient
mbl
could
thu
potenti
pathogen
factor
diabet
cardiovascular
complic
eg
nephropathi
hansen
saevarsdottir
et
al
normoalbuminur
type
diabet
found
higher
mbl
level
nondiabet
control
stepwis
increas
circul
mbl
level
increas
level
urinari
albumin
excret
hansen
et
al
correl
mbl
creactiv
protein
level
gener
use
marker
inflammatori
reaction
seen
anoth
studi
show
significantli
larger
proport
patient
diabet
nephropathi
present
mbl
genotyp
associ
higher
mbl
level
compar
group
mbl
genotyp
associ
low
mbl
level
saraheimo
et
al
confirm
elev
serum
mbl
level
type
diabet
patient
diabet
nephropathi
prospect
followup
studi
type
diabet
patient
found
patient
type
diabet
mbllevel
median
gml
risk
develop
micro
macroalbuminuria
patient
mbllevel
median
risk
develop
microor
macroalbuminuria
hovind
et
al
data
suggest
high
mbl
genoand
phenotyp
associ
increas
risk
develop
diabet
kidney
diseas
assess
mbl
statu
may
prove
benefici
identifi
patient
risk
microand
macrovascular
complic
indic
link
immunolog
disord
increas
risk
utero
infect
recurr
spontan
abort
rsa
line
kilpatrick
et
al
report
associ
low
mbl
level
unexplain
rsa
surprisingli
found
frequenc
mbl
defici
higher
femal
also
male
partner
coupl
rsa
respect
compar
control
anoth
studi
kilpatrick
et
al
femal
male
mbl
defici
level
overrepres
scottish
rsa
coupl
christiansen
et
al
includ
rsa
femal
male
partner
control
found
increas
frequenc
mbl
defici
femal
partner
compar
control
group
preval
mbl
defici
increas
increas
number
abort
p
anoth
studi
mbl
level
measur
women
unexplain
rsa
husband
compar
correspond
measur
coupl
uncompl
reproduct
histori
healthi
blood
donor
kruse
et
al
among
women
rsa
women
low
mbl
level
compar
control
group
p
associ
seen
matern
mbl
defici
patient
mbl
level
ngml
higher
abort
rate
patient
normal
mbl
level
p
studi
baxter
et
al
investig
rsa
coupl
kruse
et
al
see
differ
analyz
mbl
genotyp
also
baxter
et
al
includ
coupl
rsa
control
coupl
found
frequenc
mbl
genotyp
similar
two
group
appear
measur
mbl
level
genotyp
relev
group
patient
sinc
chorioamnion
usual
result
pathogen
organ
annel
et
al
examin
women
spontan
preterm
birth
week
pregnanc
divid
without
chorioamnion
establish
number
snp
immunolog
relev
gene
found
presenc
mbl
b
allel
posit
associ
chorioamnion
multivari
odd
ratio
p
annel
et
al
also
found
presenc
b
allel
significantli
multivari
odd
ratio
p
associ
preterm
birth
week
n
compar
children
born
term
n
babula
et
al
observ
higher
frequenc
mbl
variant
allel
women
vulvovagin
candidiasi
vvc
examin
patient
control
mbl
shown
present
cervicovagin
lavag
also
found
pelli
et
al
babula
et
al
also
studi
patient
vestibul
compar
control
variant
mbl
b
allel
frequent
p
mbl
level
lower
p
patient
hand
pelli
et
al
studi
women
bacteri
vaginosi
patient
vulvovagin
candidiasi
women
symptom
control
group
observ
influenc
mbl
allotyp
link
mention
studi
correl
mbl
genotyp
level
vagin
infect
fungal
bacteri
anim
result
indic
antivir
activ
mbl
gadjeva
et
al
studi
cohort
patient
genit
infect
symptomat
asymptomat
higher
frequenc
mbldefici
patient
seen
symptomat
group
compar
asymptomat
group
suggest
mbl
may
involv
clearanc
infect
investig
sure
need
seem
low
mbl
level
may
risk
factor
rsa
obstetr
complic
interest
possibl
therapi
mbl
clinic
situat
earli
trial
mbl
purifi
donor
plasma
indic
absenc
advers
effect
possibl
even
benefici
effect
valdimarsson
et
al
reconstitut
mbl
defici
individu
safeti
mbl
infus
born
phase
studi
valdimarsson
et
al
number
consider
led
us
exploit
possibl
produc
clinic
grade
recombin
mbl
rmbl
promis
result
led
establish
compani
aim
phase
trial
rmbl
success
conclud
mani
mbldeficiencyassoci
clinic
condit
mention
would
theoret
candid
reconstitut
treatment
one
must
initi
aim
investig
small
defin
patient
group
rel
short
followup
period
immunodefici
select
patient
chemotherapyinduc
neutropenia
sirssepsi
patient
obvious
better
definit
patient
may
need
treatment
chronic
disord
may
possibl
also
consid
longer
term
creation
mbl
knockout
mice
made
possibl
experiment
investig
effect
mbl
defici
mous
two
gene
encod
differ
mbl
molecul
mbla
c
compar
one
human
mbl
mice
abl
bind
carbohydr
surfac
activ
complement
system
slight
differ
carbohydr
specif
report
two
mous
mbl
mice
mbla
knockedout
first
produc
mice
mbla
c
knock
mbl
dko
suitabl
anim
model
human
mbl
defici
sepsi
model
staphylococcu
aureu
inject
via
tail
vein
lack
mbl
lead
significantli
increas
mortal
infus
recombin
mbl
revers
phenotyp
differ
seen
bacteria
inject
intra
periton
howev
mice
treat
cyclophosphamid
simul
chemotherapyinduc
neutropenia
intra
periton
infect
mbl
dko
abscess
wild
type
mbl
dko
mice
also
suscept
challeng
herp
simplex
viru
type
gadjeva
et
al
line
suggest
involv
mbl
autoimmun
diseas
mbl
dko
mice
examin
autoimmun
symptom
stuart
et
al
sign
observ
hand
found
abil
clear
apoptot
cell
less
effici
mbl
knockout
hypothes
mbl
bind
significantli
healthi
tissu
chang
due
abnorm
condit
might
reveal
mbl
ligand
inde
mbl
express
tumor
cell
line
gene
therapi
mblvaccinia
construct
found
protect
nude
mice
transplant
human
colorect
cancer
cell
line
et
al
vitro
studi
indic
bind
mbl
cell
expos
hypoxiareoxygen
simul
ischemiareperfus
subsequ
shown
infus
block
antimbl
antibodi
would
protect
myocardi
destruct
follow
ischemiareperfus
rat
model
jordan
et
al
use
mbl
dko
mice
et
al
found
model
kidney
ischemia
reperfus
ir
injuri
mbl
dko
partial
protect
evidenc
better
kidney
function
mice
ischemiareperfus
increas
deposit
complement
factor
seen
wild
type
mice
bind
mbl
section
kidney
could
inhibit
mannos
agreement
de
vri
et
al
found
mbla
c
deposit
kidney
ischemiareperfus
mbl
wild
type
mice
bound
microorgan
mblmasp
complex
effici
activ
complement
ensu
kill
foreign
agent
one
would
thu
priori
expect
signific
manifest
mbl
defici
accordingli
abund
evid
associ
suscept
infect
mbl
defici
appear
surfac
certain
clinic
situat
element
immun
system
compromis
immun
defenc
abund
redund
surviv
individu
ensur
manifold
defenc
mechan
subtl
regulatori
role
mbl
indic
preval
mbl
defici
autoimmun
disord
suggest
new
avenu
investig
